Yeah, I know their products are good from first hand experience. The only thing weighing on my mind right now is the phase II trial results. Interstitial Cystitis is a difficult disease to treat because the diagnosis is largely symptom based and many doctors believe there is different etiology in different cases. Showing efficacy good enough for the FDA has been difficult because of that, and margins are usually somewhat small over placebo. But hopefully the FDA will have realized this at this point and take that into consideration. Also they should consider Uracyst has pretty much no side effects or risk.
News 
Market Data 
Discover 
